It is very unlikely that $Merck(MRK)$ Merck would take such a chance, when there is no need to do so.
Read the Ridgeback and UNC paper on their Molnupiravir trial. The only death that occurred was one of the patients who had been administered a placebo. ALL of the patients on Molnupiravir were virus free by day 5, compared to 11.5% people who had virus even after day 5.
There does not appear to be doubt about whether it works - safety also does not appear to be an issue.
精彩评论